Orphan Drug Act’s ‘nonprofitability’ loophole needs to be closed – STAT
A provision in the Orphan Drug Act that lets a drug company earn orphan status for a drug that will not be profitable needs to be tweaked.
Related Articles
What the threatened Medicaid cuts look like, and Humana’s Villages play
This is the online version of STAT’s weekly email newsletter Health Care Inc.
Study finds no evidence aluminum salts in vaccines are tied to higher risk of asthma, other childhood diseases
A new large study from Denmark finds no evidence that aluminum salts used in vaccines are tied to a higher risk of childhood diseases.
25 years ago, I reported on horrifying hospital errors. Here’s what’s changed since then — and what hasn’t
Twenty-five years ago, Larry Tye reported on hospital errors for the Boston Globe. His recent wrist surgery showed just how much things have changed since…
Court-ordered treatment for serious mental illness is ‘inconclusive,’ says federal report
Evidence is lacking to show whether involuntary treatment for serious mental illness works, GAO says.
The links between different gun laws and types of gun deaths
And more health news stories to get you started for the week.
Ozempic for addiction: How an elite rehab center is using GLP-1s to ‘obliterate’ all kinds of cravings
Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.
Reports of young children accidentally eating nicotine pouches rose 763% in three years: Study
Young children accidentally eating nicotine pouches are on the rise, with potentially serious consequences.
The growing influence of vaccine skeptics inside HHS
The growing influence of vaccine critics inside RFK Jr.’s health department is alarming public health experts.
FDA declines to approve Ultragenyx gene therapy
And more biotech news updates, brought to you by The Readout.
Pharmalittle: We’re reading about GLP-1 drugs for addiction, FDA funding, and lots more
A Trump administration proposal to consider another form of drugs for Medicare price cuts is spurring legal and policy concerns from pharma